Clozapine

BUDAPEST, Hungary, April 8, 2025 /PRNewswire/ -- At the 33rd Annual Meeting of the European Psychiatric Association (EPA; 5-8th April, Madrid), new analyses of cariprazine studies were presented by Gedeon Richter Plc. The scientific posters showed that cariprazine seems to be an appropriate treatment option for a difficult-to-treat patient population, schizophrenia patients with multiple psychotic episodes and cannabis use disorder. Three further scientific posters were presented, and a joint session with partner company Recordati was organized focusing on the advantages of treatment with third generation antipsychotics. Finally, a novel transdiagnostic scale for quantifying and visualizing the severity of symptoms in patients with different psychiatric conditions was also shown at EPA. The first scientific poster evaluated the effectiveness of cariprazine in dual schizophrenia patients with multiple schizophrenia episodes and cannabis use disorder. The results of the 6-month observational study showed that cariprazine seems to be an effective treatment option for this patient population. The second poster showed that the sex of patients does not seem to significantly influence risk of relapse, and that cariprazine decreases the risk of relapse compared to placebo in both males and females. The third poster evaluated the progression and treatment of negative symptoms in female patients during their hospital-stay. Importantly, results indicated cariprazine to be the first choice of medication both as mono- and polytherapy, resulting in significant decrease of negative symptoms during hospitalization. Finally, the fourth poster collected all available evidence on cariprazine-clozapine augmentation strategy, showing that it appears to be promising for treatment-resistant schizophrenia, particularly for negative symptoms with favorable safety outcomes. In addition, Richter and Recordati organized a scientific symposium titled " Partial activity, full impact: innovations in schizophrenia treatment", where experts discussed the potential of dopamine receptor partial agonists and the importance of understanding the mechanism of action to differentiate and personalize therapies. On the 4th of April, during a Scientific Event involving around 100 doctors, the importance of utilizing measurement-based care in everyday psychiatric practice was highlighted: Professor Christoph U. Correll and an expert from Gedeon Richter presented a novel transdiagnostic scale for quantifying-visualizing symptom severity in patients with different psychiatric conditions. Cariprazine is available in 67 countries globally, and the number of total patients treated from launch in Europe and US is around 1.700.000 (different indications). About Richter About Recordati About Cariprazine Media-contact: Zsuzsa Beke, Head of PR, [email protected] WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

English 繁體中文 “Ω-NaBen exemplifies a novel molecular entity much improves the biophysicochemical properties of the sodium benzoate.” Dr. Guochuan Emil Tsai said. Los Angeles, California, March 18, 2025 A recent study by SyneuRx has revealed superior pharmaceutical properties of Ω(omega)-NaBen, a novel crystalline form of sodium benzoate (NaBen). Ω-NaBen is the last alphabet of Greek. Ω-NaBen reflects the ultimate supreme value of the Nostradamus compound he first discovered and purified in 1556. In the study, Ω-NaBen can therapeutically improve all three major symptom domains of schizophrenia model, including positive, negative, and cognitive symptoms. Ω-NaBen also shows enhanced aqueous solubility and therefore improves the bioavailability and antipsychotic effects. In addition, Ω-NaBen also has much better crystal-stability either by itself or combined clozapine. The findings of Ω-NaBen have been published in the peer-reviewed journal, CNS & Neurological Disorders – Drug Targets. NaBen can increases the synaptic D-serine level to enhance NMDA receptor-mediated neurotransmission and therapeutically improve the symptoms of schizophrenia and cognition and memory of dementia. Nevertheless, the therapeutic effect is not dose-efficient due to the low bioavailability, therefore requires large unrealistic dosages. To improve NaBen, SyneuRx have discovered all crystalline forms of NaBen. Among them, Ω-NaBen exhibits exceptional bioavailability and therapeutic effects in the preclinical study. A multi-center clinical study (ClinicalTrials.gov Identifier: NCT03094429) is currently ongoing for assessing the safety and efficacy of Ω-NaBen as an add-on therapy with clozapine in refractory schizophrenia. Once developed successfully, the combination of clozapine and Ω-NaBen, a novel and superior crystalline NaBen, can work as a therapy beyond the last line treatment of schizophrenia—clozapine therapy. Professor Dr. Guochuan Emil Tsai from UCLA, highlighted, “Ω-NaBen exemplifies an effective strategy for the patients with schizophrenia and taking the last line of treatment, clozapine; it extend the frontier of the treatment of schizophrenia.” Privacy PolicyTerms of Use Contact Mission Leadership Team Major Milestone Antiviral Platform NMDA Platform Pipeline SNA11 SNG12 SND12 Press Release Publication Media